Superficial Cervical Plexus Block With Dexmedetomidine Versus Without Adjuvant in Thyroid Surgery
CompletedNot applicableNCT07274670
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Efficacy of Superficial Cervical Plexus Block (SCPB) with Dexmedetomidine Adjuvant Compared to Without Adjuvant in Thyroid Surgery. This is a double-blinded, randomized controlled trial designed to evaluate the effectiveness of adding perineural dexmedetomidine to a Superficial Cervical Plexus Block (SCPB) for pain management in patients undergoing thyroid surgery. The study aims to prove that SCPB with dexmedetomidine adjuvant provides superior post-operative analgesia, lowers total opioid consumption, prolongs the time until the first analgesic request, and reduces the incidence of chronic pain three months post-surgery compared to SCPB without the adjuvant. The study will also evaluate the anti-inflammatory effect by measuring the reduction in Interleukin-6 (IL-6) levels post-operatively and compare the incidence of bradycardia as a side effect. The total required sample size is 58 subjects.
Study details
- Official title
- A Randomized Double-Blind Controlled Trial on the Effectiveness of Superficial Cervical Plexus Block With Dexmedetomidine Compared to Without Adjuvant in Thyroid Surgery
- Conditions
- Thyroid Cancer
- Goiter
- Hyperthyroidism
- Interventions
- Drug: Dexmedetomidine & Bupivacaine.
- Drug: Bupivacain
- Sponsor
- Udayana University
- Start date
- 2025-07-01
- Primary completion
- 2025-10-30
- Sex
- All
- Age range
- from 30 Years to 59 Years
- Results posted
- No results posted in this snapshot
- Countries
- Indonesia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged 30-59 years. * Patients with ASA physical status classification I-III. * Patients with Body Mass Index (BMI) between 18 and 25 kg/m Exclusion Criteria: * Patients with contraindications for regional anesthesia. * Patients with a history of autoimmune disease. * Presence of infection in the puncture area. * Patients with allergies and contraindications to the use of dexmedetomidine. * Patients on routine medication, including beta-blockers, anti-depressants, or anti-seizure medications. * Prolonged opioid use. * Patients unable to be assessed using the Visual Analogue Scale (VAS) or unable to operate the Patient-Controlled Analgesia (PCA) device. * Patients who refuse to participate in the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07274670